KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Gains from Investment Securities: 2010-2025

Historic Gains from Investment Securities for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Sep 2025 value amounting to -$4.8 million.

  • Regeneron Pharmaceuticals' Gains from Investment Securities fell 103.99% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.3 million, marking a year-over-year decrease of 81.03%. This contributed to the annual value of $1.0 billion for FY2024, which is 18.25% up from last year.
  • As of Q3 2025, Regeneron Pharmaceuticals' Gains from Investment Securities stood at -$4.8 million, which was down 135.82% from $13.4 million recorded in Q2 2025.
  • Regeneron Pharmaceuticals' Gains from Investment Securities' 5-year high stood at $1.2 billion during Q4 2022, with a 5-year trough of -$347.1 million in Q2 2021.
  • Its 3-year average for Gains from Investment Securities is $173.8 million, with a median of $120.2 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Regeneron Pharmaceuticals' Gains from Investment Securities was 2,614.13% (2021), while the steepest drop was 183.34% (2021).
  • Quarterly analysis of 5 years shows Regeneron Pharmaceuticals' Gains from Investment Securities stood at $768.1 million in 2021, then surged by 62.19% to $1.2 billion in 2022, then plummeted by 49.61% to $627.8 million in 2023, then slumped by 59.64% to $253.4 million in 2024, then crashed by 103.99% to -$4.8 million in 2025.
  • Its Gains from Investment Securities stands at -$4.8 million for Q3 2025, versus $13.4 million for Q2 2025 and $4.3 million for Q1 2025.